Deirdre Tessman, Ph.D.
Managing Director, Medelis Europe
Formerly of Tessman Technology Ltd. and ILEX Pharmaceuticals, Dr. Deirdre Tessman brings more than 30 years of worldwide drug development and regulatory experience to the Medelis organization. She has directed all phases of pharmaceutical development from research through drug approval and marketing with additional expertise in the startup and turnaround of pharmaceutical companies.
As Managing Director of Medelis Europe, Dr. Tessman brings 10 years of experience managing European studies, an extensive understanding of European regulatory requirements and a deep familiarity with all phases of clinical development to Medelis clients who wish to complete the regulatory requirements of the European Community for their therapies and devices.
From 1997-2001, Dr. Tessman provided contract research services to clients in Europe and the U.S. as the Managing Director/Senior Vice President, European Operations for ILEX Services Limited. In 2001, she acquired the CRO business from ILEX and transformed it into Tessman Technology, a successful privately-held oncology CRO and clinical investigator network offering clinical monitoring services in both the U.S. and the European community.
Prior to her success in the CRO industry, Dr. Tessman served as the Vice President, Drug Development for ILEX Pharmaceuticals. In that role, she established and led a drug development infrastructure of 130+ employees including regulatory, clinical research, medical writing, project management, biostatistics, data management and business support personnel. She led drug development of ILEX-sponsored and contract-based projects and served as the company’s primary liaison with NCI, opinion leaders, investigators, CROs and pharmaceutical company collaborators.
Dr. Tessman previously served as Director, Worldwide Pharmaceutical Projects for Schering AG, where she led the company’s first global project management team in obtaining EMEA approval of a small molecule oncology drug. She has also served as the Director, Pharmaceutical Projects for Triton Biosciences and spent 20 years with Warner-Lambert/Parke-Davis, where she directed cardiovascular clinical development.
Dr. Tessman has also been named to the Top 100 Business Women in Scotland and was awarded a Leukemia Society of America award for her contributions to the leukemia therapy field. She received a Doctor of Philosophy in Business Administration from California Coast University, an M.B.A. from the University of Michigan, and a Bachelor of Science from Margrove College.
« return
